Glofitamab for lymphoma that did not respond or returned early
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how well a medicine called glofitamab works and how safe it is for people with a type of blood cancer (diffuse large B-cell lymphoma) that did not respond to first treatment or came back within a year. If you qualify, you may receive glofitamab as part of your care, and the study will track your progress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a confirmed diagnosis of diffuse large B-cell lymphoma (a type of blood cancer).
- Your lymphoma must be primary refractory (did not respond to first treatment) or have relapsed within 12 months of achieving remission.
- You should be planning to start a treatment that includes the drug glofitamab (alone or with other treatments) within 12 months.
- You must be willing to follow up with the study team and provide data.
- You cannot be taking part in any other interventional clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called glofitamab for people with a type of lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The goal is to see if this drug can help shrink tumors or stop the disease from progressing.
This trial combines two treatments for large b-cell lymphoma that has come back or not responded to previous therapy. Glofitamab is a drug that helps the immune system attack cancer cells, and CAR-T therapy uses your own white blood cells, which are modified in a lab to find and kill cancer cells. This study aims to see if the two treatments together are safe and effective.
This study tests an extra treatment called glofitamab (given as an infusion) after your first therapy has worked well, to help keep the lymphoma from coming back. It is for people with high-risk large B-cell lymphoma, and aims to improve long-term remission.
This study looks at how well a type of immunotherapy called a bispecific antibody works for people whose B-cell lymphoma has come back or not responded to previous treatments. It aims to see if this treatment can help control the cancer and improve outcomes.
This study looks at how well a new drug called glofitamab works in real life for people with a type of lymphoma that has come back or not improved after treatment. It aims to see if the drug is safe and effective outside of a clinical trial setting.
This trial tests a drug called glofitamab for people with aggressive B-cell lymphomas (like DLBCL or mantle cell lymphoma) that have come back or not responded to standard treatments. The study uses a biopsy during treatment to see how the drug is working, aiming to make treatment more personalized.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.